OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 02:27:15 2024-05-24 pm EDT | ||
| 26.62 EUR | -2.35% |
|
| Current month | -18.87% | ||
| 1 month | -16.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 26.62 | -2.35% |
| 24-05-23 | 27.26 | -0.66% |
| 24-05-22 | 27.44 | -2.38% |
| 24-05-21 | 28.11 | +2.44% |
| 24-05-20 | 27.44 | -0.90% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 02:27 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1BU7 |
| ISIN | DE000GG1BU76 |
| Date issued | 2023-12-19 |
| Strike | 744 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 30.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.11 € |
|---|---|
| Lowest since issue | 26.62 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
